These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3487647)

  • 1. Complement activation in systemic lupus erythematosus: a marker of inflammation.
    Kerr LD; Adelsberg BR; Spiera H
    J Rheumatol; 1986 Apr; 13(2):313-9. PubMed ID: 3487647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new and rapid quantitative assay for complement activation: an ELISA for C3d.
    Adelsberg BR; Kerr LD; Spiera H
    Diagn Immunol; 1985; 3(4):187-90. PubMed ID: 3878762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease.
    Bourke BE; Moss IK; Mumford P; Horsfall A; Maini RN
    Clin Exp Immunol; 1982 Jun; 48(3):726-32. PubMed ID: 6981475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating immune complex levels measured by new ELISA kits utilizing monoclonal anti-C1q and anti-C3d antibodies correlate with clinical activities of SLE but not with those of RA.
    Yoshinoya S; Mizoguchi Y; Aotsuka S; Yokohari R; Nishioka K; Miyamoto T
    J Clin Lab Immunol; 1992; 38(4):161-73. PubMed ID: 11270517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement degradation product C3d in urine: marker of lupus nephritis.
    Negi VS; Aggarwal A; Dayal R; Naik S; Misra R
    J Rheumatol; 2000 Feb; 27(2):380-3. PubMed ID: 10685801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
    Perrin LH; Lambert PH; Miescher PA
    J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.
    Sekita K; Doi T; Muso E; Yoshida H; Kanatsu K; Hamashima Y
    Clin Exp Immunol; 1984 Mar; 55(3):487-94. PubMed ID: 6608422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation.
    Arason GJ; Steinsson K; Kolka R; Víkingsdóttir T; D'Ambrogio MS; Valdimarsson H
    Rheumatology (Oxford); 2004 Jun; 43(6):783-9. PubMed ID: 15054157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
    Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
    Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.
    Morrow WJ; Williams DJ; Ferec C; Casburn-Budd R; Isenberg DA; Paice E; Snaith ML; Youinou P; Le Goff P
    Ann Rheum Dis; 1983 Dec; 42(6):668-71. PubMed ID: 6606402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. inverse association with anti-dsDNA antibodies.
    Voss A; Nielsen EH; Svehag SE; Junker P
    J Rheumatol; 2008 Apr; 35(4):625-30. PubMed ID: 18278838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
    Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
    J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
    Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K
    Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.
    Röther E; Lang B; Coldewey R; Hartung K; Peter HH
    Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
    Senaldi G; Makinde VA; Vergani D; Isenberg DA
    Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reticulocytes bearing C4d as biomarkers of disease activity for systemic lupus erythematosus.
    Liu CC; Manzi S; Kao AH; Navratil JS; Ruffing MJ; Ahearn JM
    Arthritis Rheum; 2005 Oct; 52(10):3087-99. PubMed ID: 16200588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of classical pathway complement in chronic inflammation. Elevated levels of circulating C3d and C4d split products in rheumatoid arthritis and Crohn's disease.
    Petersen NE; Elmgreen J; Teisner B; Svehag SE
    Acta Med Scand; 1988; 223(6):557-60. PubMed ID: 3389208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus.
    Li J; An L; Zhang Z
    Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.